Laurie D. Stelzer

2016

In 2016, Laurie D. Stelzer earned a total compensation of $1.9M as Senior Vice President and Chief Financial Officer at Halozyme Therapeutics, a 51% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$207,000
Option Awards$500,013
Salary$435,000
Stock Awards$749,997
Other$8,643
Total$1,900,653

Stelzer received $750K in stock awards, accounting for 39% of the total pay in 2016.

Stelzer also received $207K in non-equity incentive plan, $500K in option awards, $435K in salary and $8.6K in other compensation.

Rankings

In 2016, Laurie D. Stelzer's compensation ranked 5,114th out of 14,075 executives tracked by ExecPay. In other words, Stelzer earned more than 63.7% of executives.

ClassificationRankingPercentile
All
5,114
out of 14,075
64th
Division
Manufacturing
1,825
out of 5,489
67th
Major group
Chemicals And Allied Products
580
out of 1,895
69th
Industry group
Drugs
435
out of 1,538
72nd
Industry
Biological Products, Except Diagnostic Substances
76
out of 279
73rd
Source: SEC filing on March 24, 2017.

Stelzer's colleagues

We found four more compensation records of executives who worked with Laurie D. Stelzer at Halozyme Therapeutics in 2016.

2016

Helen Torley

Halozyme Therapeutics

Chief Executive Officer

2016

Mark Gergen

Halozyme Therapeutics

Chief Operating Officer

2016

Athena Countouriotis

Halozyme Therapeutics

Chief Medical Officer

2016

Harry Leonhardt

Halozyme Therapeutics

General Counsel

News

You may also like